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httcense.Abstract Purpose: The goal of this studywas to assess the value of combinedPET/CT in the restaging
of suspected recurrent cancer and its impact on further management planning of the patients.
Patients and methods: Fourty-two patients with suspected recurrence due to new clinical, biochemi-
cal and radiologic ﬁndings were prospectively evaluated. PET/CT results were compared with PET
andCT data. A ﬁnal diagnosis of recurrence was conﬁrmed by biopsy or by further clinical and radio-
logic work-up.
Results: Thirty nine out of 42 patients had recurrence and or distant metastases in 108 malignant
sites. For the site-based analysis PET/CT showed 100% sensitivity, 80% speciﬁcity, 98% PPV,
100% NPV and 98% accuracy compared with 100%, 50%, 94%, 100% and 95%, respectively, for
PET, and 87%, 50%, 94%, 28% and 83%, respectively, for CT. For the patient-based analysis,
PET/CT showed 100% sensitivity, 75% speciﬁcity, 97% PPV, 100% NPV and 98% accuracy com-
pared with 100%, 50%, 92%, 100% and 93%, respectively for PET and 86%, 75%, 97%, 38%
and 86%, respectively for CT. PET/CT results changed the management of 90% of patients.
Conclusion: PET/CTprovides accurate restaging of suspected recurrent cancerwith a signiﬁcant clin-
ical impact on further management planning.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.001155301.
(D.Z. Zidan).
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Detection and exact localization of recurrent lesions are
critical for guiding management and determining the proper
therapeutic approach, which may prolong survival (1). Com-
puted tomography (CT) is currently considered the modality
of choice for diagnosis of local or distant recurrent cancer,
due to its wide availability and low cost (2). However, CT-
based diagnosis of treatment-induced necrotic or ﬁbrotic tissue
versus viable residual or recurrent cancer is difﬁcult and some-
times impossible (3,4).gyptian Society of Radiology and Nuclear Medicine.
.03.003
322 D.Z. Zidan et al.Positron emission tomography/Computed tomography
(PET/CT) opens new pathways for the optimized management
of recurrent cancer (5).
The goal of this study was to assess the value of
combined PET/CT in the restaging of suspected recurrent
cancer and its impact on further management planning of
the patients.2. Patients and methods
2.1. Patients
Forty-two patients with a known primary neoplasm were re-
ferred for 18F-ﬂuoro-2-deoxy-D-glucose (18F-FDG) PET/CT
between June 2010 and June 2012.
The cause for referral was the suggestion of recurrent can-
cer on the basis of clinical, laboratory or suspicious imaging
ﬁndings.
This study included 30 females and 12 males with age rang-
ing from 12 to 70 years (mean age 52 years).
The inclusion criteria for this prospective study included (a)
cancer patients during follow-up after complete successful
surgical treatment for their known primary tumor (b) at least
6 months after initial surgery (c) clinical or laboratory suspi-
cion of tumor recurrence and (d) uncertain diagnosis of recur-
rent disease or its extent after routine CT, magnetic resonance
imaging or bone scintigraphy work-up.
2.2. PET/CT acquisition and processing
Whole-body positron emission tomography (PET) was per-
formed with a hybrid PET/CT scanner (Siemens Biograph 64
PET/CT scanner). Patients were instructed to fast, except for
glucose-free oral hydration, for at least 6 h before undergoing
the examination. All patients were asked to avoid (extreme)
exercise for at least 6 h before the study to minimize FDG up-
take in muscles. Blood glucose was measured before injection
of the tracer to ensure glucose blood levels of <200 mg/dL.
IV injection of approximately 5 MBq/kg body weight of
FDG was given and then data were acquired 60–90 min later.
After injection of the tracer, patients were kept lying comfort-
ably and were asked not to talk. They were also kept warm
throughout the study.
Approximately 60 min after the tracer injection, 120 ml of
iodinated contrast agent was intravenously administered to
perform a contrast-enhanced CT scan from mid thigh to the
skull base with the arms extended above the head, that was ob-
tained on a 64 multidetector biograph scanner (which is a com-
ponent of the hybrid PET/CT scanner) with a collimator width
of 5.0 mm, 120 mAs, 130 kVp and 5 mm slice thickness. A
PET scan was obtained immediately after the CT scan without
allowing the patient to move on the gantry table between the
two acquisitions so that the images can be accurately coregis-
tered. The Siemens Biograph 64 includes special full-ring PET
detectors based on lutetium oxyorthosilicate (LSO). Axial ﬁeld
of view of 15 cm was applied and multiple overlapping bed
positions (5 min/bed position) were used. All PET, CT and
PET/CT images were reviewed on a dedicated fusion imaging
workstation (Syngo-based Windows platform) and were dis-
played in axial, coronal, and sagittal planes.2.3. Study interpretation and analysis of PET/CT images
A combined team, including one nuclear medicine physician
and one radiologist, interpreted the PET, CT and fused
PET/CT images. They were aware of each patient’s history
and clinical data.
2.3.1. For lesion based analysis
All sites of abnormal FDG uptake were recorded and assessed
quantitatively by measuring the maximum standardized up-
take value (SUV max) for every lesion. Although the degree
to which both benign and malignant tumors accumulate
FDG can be quite variable, malignant tumors tend to have
SUV values greater than 2.0–2.5. Abnormalities detected in
the enhanced CT portion of the PET/CT study were recorded
and lymphnode assessment was based on size criteria (short
axis more than 10 mm was considered positive for malignancy)
then each lesion in the fused PET/CT images was also evalu-
ated. Changes in lesion deﬁnition and localization provided
by PET/CT were recorded.
Our standard of reference was histopathologic examination
or clinical and imaging follow-up evaluation for at least
6 months. A suspected tumor site was considered true-positive
if the histologic ﬁndings were positive or if the lesion exhibited
progression at 6 months of follow-up imaging.A lesionwas con-
sidered true-negative if the histologic ﬁndings were negative or
the lesion disappeared or was found unchanged at follow-up
imaging andwithout clinical deterioration for at least 6 months.
2.3.2. For patient based analysis
A CT, PET or PET/CT study that showed at least 1 site char-
acterized as malignant and that was further conﬁrmed to be
malignant, was deﬁned as true positive and studies with all
lesions deﬁned as benign and showed no evidence of active
cancer for at least 6 months were deﬁned as a true-negative
study. Study of a patient with positive CT, PET or PET/CT
who had no evidence of malignancy on biopsy or other imag-
ing modalities, or a negative clinical follow-up of at least
6 months, was classiﬁed as false-positive, on the other hand
a negative CT, PET or PET/CT study in a patient who had
further evidence of malignancy during the follow up was de-
ﬁned as false-negative.
2.3.3. For PET/CT impact on management
The impact of fused PET/CT images on the management of
patients was evaluated by recording referral of patients for pre-
viously unplanned therapeutic modalities based on PET/CT
results, this information was obtained from patients’ ﬁles.
3. Results
Forty-two patients with histopathologically proven resected
primary malignancy (Table 1), were evaluated for suspected
recurrence and restaging using combined PET/CT. Local
recurrence was the ﬁnal diagnosis in 29 patients, 15 out 29
had associated distant metastases, distant metastases without
local recurrence was conﬁrmed in 10 patients and negative
for recurrence or distant metastases in three patients.
Table 1 number of cases and their histopathologically proven
resected primary malignancy in the 42 patients.
No of cases Primary malignancy
12 Cancer breast
10 Bronchogenic carcinoma
7 Cancer colon
5 Osteogenic sarcoma
4 Giant cell tumor
3 Liposarcoma
1 Adrenal carcinoma
Table 2 The results of CT, PET and PET/CT, histopathology
and/or follow up for assessment of 108 lesions in 39 patients.
No. of
sites
CT 18F-FDG
PET
PET/CT Histopathology
and/or follow up
85 TP TP TP POSITIVE
13 FN TP TP POSITIVE
5 FP TN TN NEGATIVE
3 TN FP TN NEGATIVE
2 TN FP FP NEGATIVE
TP: true-positive; TN: true-negative; FP: false-positive; FN: false-
negative; PPV: positive predictive value; NPV: negative predictive
value.
Fig. 1 A 49-year-old man with left bronchogenic carcinoma, after sur
progressive weight loss. He was referred to PET/CT due to clinical s
solitary left deep cervical lymphnode considered non-malignant acco
metabolically active 18F-FDG avid left deep cervical lymphnode (arr
location of the metabolically active 18F-FDG avid left deep cervical ly
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patients: site-based analysis
There were 108 sites in the 39 patients evaluated (Table 2).
Based on PET, CT and PET/CT, 85 lesions were characterized
as malignant and conﬁrmed histopathologically or on follow-
up imaging. PET and PET/CT enabled the retrospective detec-
tion of 15 lesions missed or not considered pathologic on CT,
including 2 cervical, 3 mediastinal and 2 abdominal lymph
nodes (8–10 mm in size) (Fig. 1), 1 periprothesis recurrence
(Fig. 2), 3 posttreatment ﬁbrosis (Fig. 3) and 2 rib, 1 sternal
and 1 left pedicle metastases (Figs. 4 and 5). Malignancy was
conﬁrmed in 13 out of 15 sites by histologic specimens ob-
tained at surgery or by changes on follow-up imaging. On
the other hand 2 out of 15 were interpreted as false-positive
in PET and PET/CT studies as they were negative for malig-
nancy in histopathological results, these two lesions were
inﬂammatory lymphnodes with relatively high SUV 3 but nor-
mal size in CT study. In ﬁve sites the CT study was deﬁned as
positive for malignancy (lymph nodes 20 mm) and local recur-
rence, whereas the PET and PET/CT studies were negative as
these lymphnodes were reactionary and the local recurrence
was posttreatment ﬁbrosis. None of these ﬁve sites developed
a recurrence on 6 months of follow-up. In three lesions the
PET study was deﬁned as positive, whereas the PET/CT studygical removal of primary tumor. He complained from anorexia and
uspicion of metastases. (a) Axial contrast-enhanced CT shows a
rding to CT based size criteria. (b) FDG PET shows a solitary
ow) with maximum SUV= 6. (c) Fused PET/CT conﬁrmed the
mphnode (arrow).
Fig. 2 Fourteen-year-old female patient, a known case of giant cell tumor, underwent surgical excision and knee prosthesis implantation
2 years ago. The cause of referral was localized knee pain with clinical suspicion of local recurrence. (a) Axial contrast-enhanced CT shows
metallic artifact from the prosthesis and no deﬁnite tumoral recurrence could be elicited. (b) FDG PETshows metabolically active 18F-
FDG avid right distal medial femoral condyle with max. SUV  15.6, consistent with tumoral recurrence.
Fig. 3 A 47-year-old man with left cortical adrenal carcinoma, after surgical removal of primary tumor and left nephrectomy, was
assessed for recurrence due to elevated steroid level during his routine hormonal analysis. (a) Axial contrast-enhanced CT shows ﬁbrous
strands at operative bed (arrow), yet no evidence of enhancing recurrent mass. (b) FDG PET shows metabolically active 18F-FDG avid
recurrent focal mass lesion at operative bed measuring 1 · 1.5 cm with maximum SUV= 11.3 (arrow). (c) Fused PET/CT conﬁrmed the
location of the metabolically active 18F-FDG avid recurrent focal mass lesion at operative bed (arrow).
324 D.Z. Zidan et al.was negative. PET/CT accurately localized increased 18F-FDG
uptake to physiological bowel activity in these three lesions
(Fig. 5).
According to the above data we calculated and compared
the performance indices of CT, PET and PET/CT for charac-
terization of 108 lesions in 39 patients as regards sensitivity,speciﬁcity, positive predictive value (PPV), negative predictive
value (NPV) and accuracy (Table 3).
PET/CT showed sensitivity of 100%, speciﬁcity of 80%,
PPV of 98%, NPV of 100% and accuracy of 98% compared
with 100%, 50%, 94%, 100% and 95%, respectively, for
PET, compared with 87%, 50%, 94%, 28% and 83%, respec-
tively, for CT data.
Fig. 4 Sixty year-old female patient had breast cancer 12 years ago, underwent right radical mastectomy. Her last bone scan revealed a
suspicious metastatic deposit in sternum and PET/CT was recommended. (a) Axial contrast-enhanced CT shows right hilar
lymphadenopathy measuring 1.2 mm (white arrow). (b) FDG PET shows metabolically active 18F-FDG avid bilateral hilar
lymphadenopathy (white and red arrows) and sternal osseus metastatic deposit (yellow arrow). (c) Fused PET/CT conﬁrmed the
location of the metabolically active 18F-FDG avid hilar lymphadenopathy (white and red arrows) and sternal osseus metastatic deposit
(yellow arrow). The left hilar lymphnode and metastatic deposit in sternum were initially missed by CT.
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impact of PET/CT on diagnostic accuracy
Forty-two patients were evaluated for suspected recurrence or
metastases (Table 4). CT, PET and PET/CT were true negative
in 3 out of 42 patients as they had no evidence of disease dur-
ing a follow-up of 6 months. Local recurrence (Fig. 6) and or
distant metastases were the ﬁnal diagnosis in 39 patients. 38
Positive PET/CT studies were true-positive with recurrence/
metastases proven by histologic tissue sampling or imaging
during a follow-up of 6 months. On the other hand 1 positive
PET/CT study was false-positive with no evidence of disease
during 6 months of follow up. This patient had only inﬂamma-
tory changes in 18F-FDG-avid lymphadenopathy. PET/CT
showed sensitivity of 100%, speciﬁcity of 75%, PPV of 97%,
NPV of 100% and accuracy of 98%.
PET interpreted 36 of the 42 studies as TP, 3 TN, 3 FP, and
0 FN, for sensitivity of 100%, speciﬁcity of 50%, PPV of 92%,
NPV of 100% and accuracy of 93%. In three patients out of 42
the PET study was deﬁned as positive, whereas the PET/CT
study was negative as PET/CT accurately localized increased18F-FDG uptake to physiological uptake in gastrointestinal
mucosa and we considered the PET study false positive.
On the basis of CT analysis 33 of the 42 studies were TP, 3
TN, 1 FP, and 5 FN, for sensitivity of 86%, speciﬁcity of 75%,
PPV of 97%, NPV of 38% and accuracy of 86%. Four out of
the 5 FN studies were falsely interpreted as posttreatment local
ﬁbrosis and the PET study revealed FDG avid recurrence
(Fig. 3) and 1 out of the 5 FN studies was due to beam hard-
ening artifact from prosthesis that hindered the depiction of
recurrence which was noted in the PET study (Fig. 2). All these
ﬁve patients had no evidence of distant metastases.
3.3. Clinical impact of PET/CT on patient management
(Table 5) PET/CT was true negative in 3 out of 42 patients. Of
the 38 patients with true positive PET/CT studies, 14 patients
underwent surgery with curative outcome, seven patients were
referred for chemotherapy and 17 patients received combined
radio and chemotherapy. 1 out of 42 patients had false positive
PET/CT study for metastatic lymphadenopathy but histopa-
thological veriﬁcation conﬁrmed their benign inﬂammatory
Fig. 5 Fifty ﬁve-year-old female patient, underwent left radical mastectomy for cancer breast 5 years ago followed by combined CTH &
RTH. Currently the patient developed bony aches. (a) Axial contrast-enhanced CT abdomen portovenous phase shows multiple simple
hepatic cysts at the right and left hepatic lobes (arrows). (b) FDG PET shows metabolically active 18F-FDG avid hepatic focal lesion at the
periphery of the left lobe (white arrow) and the other left and right hepatic cysts do not show corresponding FDG uptake. Metabolically
active 18F-FDG avid focal osseus lesion of left pedicle is noted (with maximum SUV= 8) that was initially missed by CT (yellow arrow).
(c) Fused PET/CT conﬁrms that the focal 18F-FDG uptake corresponds to physiological uptake in gastric mucosa and no evidence of
FDG uptake in hepatic cysts and conﬁrms the left pedicle metastatic osseus deposit.
Table 3 Comparison of performance indices of CT, PET and PET/CT for characterization of 108 lesions (site-based analysis) in 39
patients.
No. of sites TP TN FP FN Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Accuracy (%)
CT 108 85 5 5 13 87 50 94 28 83
18F-FDG PET 108 98 5 5 0 100 50 94 100 95
PET/CT 108 98 8 2 0 100 80 98 100 98
326 D.Z. Zidan et al.nature. In 38 of the 42 patients (90%) further management
could be planned based only on the incremental diagnostic
data provided by PET/CT.4. Discussion
Early diagnosis of relapsing malignancies is important for
planning future therapeutic strategies which, if initiated with-
out delay, aim either to cure or to prolong disease-free survival
and to improve the quality of life of patients with cancer (5).
PET and CT may yield incongruent ﬁndings. Each modal-
ity offers only a partial solution for the diagnostic challengesof the early detection of recurrent cancer and the precise
assessment of its extent. PET/CT hybrid imaging, performed
using a single device in a single diagnostic session, combines
noninvasive structural and metabolic tumor assessment and,
therefore, provides precise anatomic localization of areas of in-
creased 18F-FDG uptake (6).
Activity related to postoperative change and healing can be
seen up to 6 months after surgery. Therefore, follow-up imag-
ing is typically delayed until at least 3 months after surgery (7).
In this study one of our inclusion criteria was that we per-
formed the PET/CT at least 6 months after initial surgery to
avoid this diagnostic error.
Table 4 Comparison of Performance Indices of PET/CT,
PET and CT based on patient-based analysis in 42 patients.
Indices PET/CT PET CT
TP 38 36 33
TN 3 3 3
FP 1 3 1
FN 0 0 5
Sensitivity 100% 100% 86%
Speciﬁcity 75% 50% 75%
PPV 97% 92% 97%
NPV 100% 100% 38%
Accuracy 98% 93% 86%
Fig. 6 Sixty three-year-old female patient, a known case of right thig
by chemotherapy, presented with local swelling and was referred for PE
sub-cutaneous soft tissue lesion at the right side of the pelvis, overlyin
seen. (b) FDG PET shows metabolically active 18F-FDG avid margin
bed with maximum SUV= 3 (arrow). (c) Fused PET/CT conﬁrmed t
posterior aspect of the local recurrence (arrow).
Table 5 PET/CT contribution to clinical management of 42 patien
No. of patients PET/CT contribution
3 No recurrence or metastases
1 False positive lymphnode metastases
14 Local recurrence
15 Local recurrence and distant metastases
9 Distant metastases
Postoperative restaging: PET/CT impact on diagnosis and management 327Although CT is considered by surgeons to be the gold
standard for assessing the resectability of cancer, it may signif-
icantly underestimate the real tumor burden (8).
CT criteria for malignancy that are based on size, such as
the presence of enlarged lymph nodes with a diameter of
15 mm or more, have been shown to represent an inaccurate
estimate of tumor involvement (9).
This CT inaccuracy in the assessment of lymphnode malig-
nant involvement was obvious in this study as some small sized
lymphnodes (<15 mm) showed high SUV value (Figs. 1 and 4)
and some large sized lymphnodes >20 mm did not show
abnormal SUV value and follow up conﬁrmed their benign
nature as they markedly regressed in size.h liposarcoma, underwent surgical excision one year ago, followed
T/CT study. (a) Axial contrast-enhanced CT shows a well deﬁned
g the right hip region (arrow). Surgical clips at operative bed are
and posterior aspect of the recurrent focal mass lesion at operative
he location of the metabolically active 18F-FDG avid margin and
ts.
PET/CT-based management
Follow up
Negative histopathological results, follow up
Curative surgery
Combined chemo and radiotherapy
Chemotherapy, and combined with radiotherapy in two patients
328 D.Z. Zidan et al.Paes et al. (10) also conﬁrmed that the advantages of FDG
PET/CT for the restaging are mostly attributed to the detec-
tion of FDG-avid, normal-sized lymph nodes.
Fibrotic or necrotic tissue that develops inside a tumor
mass after treatment cannot be differentiated by CT from a
viable malignant tumor (11). In this study three patients had
postoperative ﬁbrosis at surgical bed noted at CT study with-
out any suspicion of recurrence, but FDG PET and PET/CT
detected recurrent tumoral tissue (Fig. 3). Differentiation of
posttherapeutic alterations attributable to scarring, inﬂamma-
tion, and necrosis from residual or recurrent tumors poses
signiﬁcant problems for CT (12).
Metallic prostheses are frequently used in limb salvage ther-
apy and can result in signiﬁcant beam hardening (CT) artifact.
This degrades image quality in the surgical bed and limits eval-
uation for local tumor recurrence (13). In this study we
encountered this diagnostic problem in one patient with knee
prothesis and PET detected the local recurrence that was
impossible to detect by CT (Fig. 2) and this makes PET and
PET/CT of high diagnostic value in the detection of occult
recurrence due to the beam hardening artifact.
Cancer-related metabolic abnormalities usually precede
structural changes and are readily detected by PET. PET is a
highly sensitive imaging test for the detection of occult recur-
rences (14). In this study occult recurrence whether at opera-
tive bed or distant metastases in apparently normal
structures was detected by FDG PET and PET/CT and missed
by CT in 13 lesions (Figs. 1–5).
Although cancer relapse can be diagnosed by PET months
and even years before it becomes evident on CT, the detection
of early 18F-FDG-avid metabolic changes caused by recurrent
tumors is impaired by the intrinsic limitations of this imaging
modality (15). In this study FDG PET falsely interpreted the
abnormal tracer avid lesion as metastasis although it was attrib-
uted to physiological uptake in gastrointestinal mucosa, but the
poor spatial resolution hindered the proper diagnosis, therefore
disease was excluded by PET/CT in sites of physiologic or non-
cancerous 18F-FDG uptake in three patients (Fig. 5).
A lesion-based analysis revealed on the basis of PET/CT a
sensitivity, speciﬁcity, and accuracy of 100%, 89%, and 97%,
respectively, and a PPV and NPV of 97% and 100% and on
the basis of PET a sensitivity, speciﬁcity, and accuracy of
96%, 50%, and 85%, respectively, and a PPV and NPV of
85% and 82%, respectively (16).
In this study, according to the lesion based analysis, we
found that PET/CT showed sensitivity of 100%, speciﬁcity
of 80%, PPV of 98%, NPV of 100% and accuracy of 98%
compared with 100%, 50%, 94%, 100% and 95%, respec-
tively, for PET. Kim et al. (17) conﬁrmed a higher restaging
accuracy of PET/CT than of PET alone (88% vs. 71%).
Another patient based analysis conducted that PET/CT
showed sensitivity of 96%, speciﬁcity of 82%, NPV of 89%,
and PPV of 93% compared with 96%, 53%, 75%, and 90%,
respectively, for PET (18).
In the present study, based on patient-based analysis, PET/
CT showed sensitivity of 100%, speciﬁcity of 75%, PPV of
97%, NPV of 100% and accuracy of 98% compared with
100%, 50%, 92%, 100% and 93%, respectively, for PET
and sensitivity of 86%, speciﬁcity of 75%, PPV of 97%,
NPV of 38% and accuracy of 86%, for CT. In a patient-based
analysis conducted by Gordin et al. (19), they concluded that
PET/CT was superior to CT and PET with regard to speciﬁcity(96%, 80%, and 73%, respectively) but superior only to CT
with regard to accuracy (59% for CT, 86% for PET, and
94% for PET/CT) and sensitivity did not differ among the
three modalities (89% for PET/CT, 92% for CT, and 92%
for PET.
FDG PET/CT allows accurate staging of the disease, which
can tailor treatment planning (20).
Gordin et al. (19) and Filippi et al. (21) stated that PET/
CT altered treatment management in more than 50% of the
study population.
In this study PET/CT had changed patient management in
38 out of 42 patients (90%) as we only included patients who
were disease free after surgical removal of their primary
tumor, referred to PET/CT due to a clinical or radiological
suspicion of recurrence and this clariﬁes the discrepancy
between our study and others in the impact of PET/CT on
management.
Data on the usefulness of PET and PET/CT in surgical and
radiotherapeutic planning, for monitoring for treatment
response and recurrent disease, and on cost effectiveness are
somewhat limited and require further study (22).
Considerations about cost-effectiveness have not been part
of this study but will be necessary, as they will play an increas-
ing role in the near future as the clinical utility of PET/CT will
lead to a change in the diagnostic and management strategy of
cancer patients.
5. Conclusion
PET/CT provides accurate restaging of suspected recurrent
cancer with a signiﬁcant clinical impact on further manage-
ment planning.
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